PT  - JOURNAL ARTICLE
AU  - Daniel J Sheward
AU  - Yiqiu Yang
AU  - Michelle Westerberg
AU  - Sofia Öling
AU  - Sandra Muschiol
AU  - Kenta Sato
AU  - Thomas P Peacock
AU  - Gunilla B Karlsson Hedestam
AU  - Jan Albert
AU  - Ben Murrell
TI  - Sensitivity of BA.2.86 to prevailing neutralising antibody responses
AID  - 10.1101/2023.09.02.556033
DP  - 2023 Jan 01
TA  - bioRxiv
PG  - 2023.09.02.556033
4099  - http://biorxiv.org/content/early/2023/09/04/2023.09.02.556033.short
4100  - http://biorxiv.org/content/early/2023/09/04/2023.09.02.556033.full
AB  - A new SARS-CoV-2 variant, designated BA.2.86, has recently emerged with over 30 spike mutations relative to its parental BA.2, raising questions about its degree of resistance to neutralising antibodies. Using a spike-pseudotyped virus model we characterise neutralisation of BA.2.86 by clinically relevant monoclonal antibodies and by two cohorts of serum sampled from Stockholm, including both a recent cohort, and one sampled prior to the arrival of XBB in Sweden.Competing Interest StatementDJS is a consultant for AstraZeneca AB.